UTMD vs LMAT vs NVCR vs MMSI

For growth investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger pick with 13. 5% revenue growth year-over-year, versus -5. 8% for Utah Medical Products, Inc. (UTMD). Utah Medical Products, Inc. (UTMD) offers the better valuation at 18. 8x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate LeMaitre Vascular, Inc. (LMAT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Utah Medical Products, Inc.

(UTMD) is the cheapest at 18. 8x versus LeMaitre Vascular, Inc. at 42. 8x. On forward P/E, Utah Medical Products, Inc. is actually cheaper at 10. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: LeMaitre Vascular, Inc. wins at 1. 92x versus Utah Medical Products, Inc. 's 3. 03x — a reasonable growth-adjusted valuation.

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LMAT returned +608. 6% versus UTMD's +19. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Utah Medical Products, Inc.

(UTMD) is the lower-risk stock at 0. 55β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 298% more volatile than UTMD relative to the S&P 500. On balance sheet safety, Utah Medical Products, Inc. (UTMD) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), LeMaitre Vascular, Inc.

(LMAT) is pulling ahead at 13. 5% versus -5. 8% for Utah Medical Products, Inc. (UTMD). On earnings-per-share growth, the picture is similar: LeMaitre Vascular, Inc. grew EPS 30. 6% year-over-year, compared to -12. 1% for Utah Medical Products, Inc.. Over a 3-year CAGR, LMAT leads at 15. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Utah Medical Products, Inc.

(UTMD) is the more profitable company, earning 29. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 29. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTMD leads at 29. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, LeMaitre Vascular, Inc. (LMAT) is the more undervalued stock at a PEG of 1. 92x versus Utah Medical Products, Inc. 's 3. 03x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Utah Medical Products, Inc. (UTMD) trades at 10. 4x forward P/E versus 37. 2x for LeMaitre Vascular, Inc. — 26. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, UTMD (1.

9% yield), LMAT (0. 7% yield) pay a dividend. NVCR, MMSI do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

UTMD, LMAT pay a dividend while NVCR, MMSI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.